Drugs in development for prophylaxis of rejection in kidney-transplant recipients

References

• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–S155.
   Google Scholar
• Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996–2005. Am J Transplant. 2007;7(5 Pt 2):1359–1375.
   Web of Science ®Google Scholar
• Tolou-Ghamari Z. Nephro and neurotoxicity of calcineurin inhibitors and mechanisms of rejections: a review on tacrolimus and cyclosporine in organ transplantation. J Nephropathol. 2012;1(1):23–30.
   Google Scholar
• Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppression after renal transplantation: a systematic review. Transplantation. 2004;77(5):769–776.
   PubMed Web of Science ®Google Scholar
• Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol. 2010;5(7):1305–1311.
   PubMed Web of Science ®Google Scholar
• Silva HT Jr, Yang HC, Meier-Kriesche HU, et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation. 2014;97(6):636–641.
   PubMed Web of Science ®Google Scholar
• Budde K, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial. Am J Transplant. 2014;14(12):2796–2806.
   PubMed Web of Science ®Google Scholar
• Bunnapradist S, Ciechanowski K, West-Thielke P; et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013;13(3):760–769.
   PubMed Web of Science ®Google Scholar
• Kuglstatter A, Mueller F, Kusznir E, et al. Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 2):119–123.
   PubMedGoogle Scholar
• Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamics studies in healthy human subjects. J Clin Pharmacol. 2013;53(8):819–826.
   PubMed Web of Science ®Google Scholar
• Aspeslet L, Freitag D, Trepanier D, et al. ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc. 2001;33(1–2):1048–1051.
   PubMed Web of Science ®Google Scholar
• Gregory CR, Kyles AE, Bernsteen L, et al. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004;78(5):681–685.
   PubMed Web of Science ®Google Scholar
• Ling SY, Huizinga RB, Mayo PR, et al. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014;77(6):1039–1050.
   PubMed Web of Science ®Google Scholar
• Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013;53(12):1303–1312.
   PubMed Web of Science ®Google Scholar
• Busque S, Cantarovich M, Mulgaonkar S, et al. The PROMISE study: a phase 2B multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011;11(12):2675–2684.
   PubMed Web of Science ®Google Scholar
• Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A. 1999;96(1):185–190.
   PubMed Web of Science ®Google Scholar
• Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13(2):559–575.
   PubMed Web of Science ®Google Scholar
• Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001;1(3):220–228.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907–1915.
   PubMed Web of Science ®Google Scholar
• Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation. 1994;57(12):1701–1706.
   PubMed Web of Science ®Google Scholar
• Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997;159(11):5187–5191.
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-infinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443–453.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10(3):535–546.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12(1):210–217.
   PubMed Web of Science ®Google Scholar
• Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547–557.
   PubMed Web of Science ®Google Scholar
• Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12(3):630–639.
   PubMed Web of Science ®Google Scholar
• Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5(6):686–693.
   PubMed Web of Science ®Google Scholar
• Preston EH, Xu H, Dhanireddy KK, et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant. 2005;5(5):1032–1041.
   PubMed Web of Science ®Google Scholar
• Kanmaz T, Fechner JJ Jr, Torrealba J, et al. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation. 2004;77(6):914–920.
   PubMed Web of Science ®Google Scholar
• Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
   Web of Science ®Google Scholar
• Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin – dependent mechanism. Nat Med. 2002;8(3):247–252.
   PubMed Web of Science ®Google Scholar
• Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation. 2007;84(8):1020–1028.
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant. 2009;9(8):1732–1741.
   PubMed Web of Science ®Google Scholar
• Oura T, Yamashita K, Suzuki T, et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am J Transplant. 2012;12(7):1740–1754.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Yamashita K, Suzuki T, et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am J Transplant. 2013;13(8):1976–1988.
   PubMed Web of Science ®Google Scholar
• Goldwater R, Keirns J, Blahunka P, et al. A phase I, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant. 2013;13(4):1040–1046.
   PubMed Web of Science ®Google Scholar
• Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17 Suppl 2:17–24.
   Google Scholar
• Rostaing L, Charpentier B, Gylda M, et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Am J Transplant. 2013;13(7):1724–1733.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. Amevive (alefacept) voluntarily discontinued in the US Jan 2011. Available from: http://www.psoriasis.org/page.aspx?pid=2311. Accessed April 18, 2015.
   Google Scholar
• Zand MS. Tofacitinab in renal transplantation. Transplant Rev. 2013; 27(3):85–89.
   Web of Science ®Google Scholar
• Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009;9(8):1936–1945.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2B trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012; 12(9):2446–2456.
   Google Scholar
• Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant. 2006;6(1):27–36.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Plosker GL. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol. 2009;10(1)51–72.
   Web of Science ®Google Scholar
• Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7(7):1770–1777.
   PubMed Web of Science ®Google Scholar
• Posselt AM, Bellin MD, Tavakol M, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010;10(8):1870–1880.
   PubMed Web of Science ®Google Scholar
• Turgeon NA, Avila JG, Cano JA, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10(9):2082–2091.
   PubMed Web of Science ®Google Scholar
• Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010;90(12):1595–1601.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA statement on the voluntary withdrawal of Raptiva from the US market [press release]. Silver Spring (MD): FDA; 2009 [April 8]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149561.htm. Accessed April 18, 2015.
   Google Scholar
• Evenou JP, Wagner J, Zenke G, et al. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther. 2009;330(3):792–801.
   PubMed Web of Science ®Google Scholar
• Matz M, Naik M, Mashreqhi MF, Glander P, Neumayer HH, Budde K. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. Expert Opin Drug Metab Toxicol. 2011;7(1):103–113.
   PubMed Web of Science ®Google Scholar
• Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant. 2011;11(7):1444–1455.
   PubMed Web of Science ®Google Scholar
• Russ GR, Tedesco-Silva H, Kuypers DR, et al. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. Am J Transplant. 2013;13(7):1746–1756.
   Web of Science ®Google Scholar
• Tedesco-Silva H, Kho MM, Hartmann A, et al. Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. Am J Transplant. 2013;13(7):1757–1768.
   PubMed Web of Science ®Google Scholar
• Pascher A, De Simone P, Pratschke J, et al. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. Am J Transplant. 2015;15(5):1283–1292.
   PubMed Web of Science ®Google Scholar